Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Research output: Contribution to journalReviewResearchpeer-review

  1. Lipidomic Abnormalities During the Pathogenesis of Type 1 Diabetes: a Quantitative Review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Diabetes Management During Breastfeeding in Women with Type 1 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  3. Can Cardiovascular Epidemiology and Clinical Trials Close the Risk Management Gap Between Diabetes and Prediabetes?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

PURPOSE OF REVIEW: Hyperglucagonemia contributes significantly to hyperglycemia in type 2 diabetes and suppressed glucagon levels may increase the risk of hypoglycemia. Here, we give a brief overview of glucagon physiology and the role of glucagon in the pathophysiology of type 2 diabetes and provide insights into how antidiabetic drugs influence glucagon secretion as well as a perspective on the future of glucagon-targeting drugs.

RECENT FINDINGS: Several older as well as recent investigations have evaluated the effect of antidiabetic agents on glucagon secretion to understand how glucagon may be involved in the drugs' efficacy and safety profiles. Based on these findings, modulation of glucagon secretion seems to play a hitherto underestimated role in the efficacy and safety of several glucose-lowering drugs. Numerous drugs currently available to diabetologists are capable of altering glucagon secretion: metformin, sulfonylurea compounds, insulin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter 2 inhibitors and amylin mimetics. Their diverse effects on glucagon secretion are of importance for their individual efficacy and safety profiles. Understanding how these drugs interact with glucagon secretion may help to optimize treatment.

Original languageEnglish
JournalCurrent Diabetes Reports
Volume17
Issue number12
Pages (from-to)128
ISSN1534-4827
DOIs
Publication statusPublished - 28 Oct 2017

    Research areas

  • Journal Article, Review

ID: 51975957